Discovery and optimisation of conotoxin Vc1.1 and analogues with analgesic properties

Analgesic α-Conotoxin Binding Site on the Human GABAB Receptor

(2022) Anuja R. Bony et al.   MOLECULAR PHARMACOLOGY

Alkyne-Bridged α-Conotoxin Vc1.1 Potently Reverses Mechanical Allodynia in Neuropathic Pain Models

(2021) Alessia Belgi et al.   JOURNAL OF MEDICINAL CHEMISTRY

α-Conotoxin Peptidomimetics: Probing the Minimal Binding Motif for Effective Analgesia

(2020) Adam C. Kennedy et al.   Toxins

Medicinal chemistry, pharmacology, and therapeutic potential of α-conotoxins antagonizing the α9α10 nicotinic acetylcholine receptor

(2020) Xiao Li et al.   PHARMACOLOGY & THERAPEUTICS

α-Conotoxin Vc1.1 Structure–Activity Relationship at the Human α9α10 Nicotinic Acetylcholine Receptor Investigated by Minimal Side Chain Replacement

(2019) Xin Chu et al.   ACS Chemical Neuroscience

Conotoxins: Chemistry and Biology

(2019) Ai-Hua Jin et al.   CHEMICAL REVIEWS

Structure–Activity Studies Reveal the Molecular Basis for GABAB-Receptor Mediated Inhibition of High Voltage-Activated Calcium Channels by α-Conotoxin Vc1.1

(2018) Mahsa Sadeghi et al.   ACS Chemical Biology

Cyclic analogues of α-conotoxin Vc1.1 inhibit colonic nociceptors and provide analgesia in a mouse model of chronic abdominal pain

(2018) Joel Castro et al.   BRITISH JOURNAL OF PHARMACOLOGY

Molecular Determinants Conferring the Stoichiometric-Dependent Activity of α-Conotoxins at the Human α9α10 Nicotinic Acetylcholine Receptor Subtype

(2018) Rilei Yu et al.   JOURNAL OF MEDICINAL CHEMISTRY

Targeting of N-Type Calcium Channels via GABAB-Receptor Activation by α-Conotoxin Vc1.1 Variants Displaying Improved Analgesic Activity

(2018) Fengtao Cai et al.   JOURNAL OF MEDICINAL CHEMISTRY

RgIA4 Potently Blocks Mouse α9α10 nAChRs and Provides Long Lasting Protection against Oxaliplatin-Induced Cold Allodynia

(2017) Sean B. Christensen et al.   Frontiers in Cellular Neuroscience

Cone Snails: A Big Store of Conotoxins for Novel Drug Discovery

(2017) Bingmiao Gao et al.   Toxins

Neuropathic pain

(2017) Luana Colloca et al.   Nature Reviews Disease Primers

Structure-Activity Studies of Cysteine-Rich α-Conotoxins that Inhibit High-Voltage-Activated Calcium Channels via GABAB Receptor Activation Reveal a Minimal Functional Motif

(2016) Bodil B. Carstens et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Effects of linker sequence modifications on the structure, stability, and biological activity of a cyclic α-conotoxin

(2016) Bodil B. Carstens et al.   BIOPOLYMERS

α-Conotoxin Vc1.1 inhibits human dorsal root ganglion neuroexcitability and mouse colonic nociception via GABA B receptors

(2016) Joel Castro et al.   GUT

Less is More: Design of a Highly Stable Disulfide-Deleted Mutant of Analgesic Cyclic α-Conotoxin Vc1.1

(2015) Rilei Yu et al.   Scientific Reports

Presence of multiple binding sites on α9α10 nAChR receptors alludes to stoichiometric-dependent action of the α-conotoxin, Vc1.1

(2014) Dinesh C. Indurthi et al.   BIOCHEMICAL PHARMACOLOGY

Discovery, Synthesis, and Structure–Activity Relationships of Conotoxins

(2014) Kalyana B. Akondi et al.   CHEMICAL REVIEWS

Differential Cav2.1 and Cav2.3 channel inhibition by baclofen and α-conotoxin Vc1.1 via GABABreceptor activation

(2014) Géza Berecki et al.   JOURNAL OF GENERAL PHYSIOLOGY

Conotoxin Gene Superfamilies

(2014) Samuel Robinson et al.   Marine Drugs

Dicarba α-Conotoxin Vc1.1 Analogues with Differential Selectivity for Nicotinic Acetylcholine and GABAB Receptors

(2013) Bianca J. van Lierop et al.   ACS Chemical Biology

Determination of the α-Conotoxin Vc1.1 Binding Site on the α9α10 Nicotinic Acetylcholine Receptor

(2013) Rilei Yu et al.   JOURNAL OF MEDICINAL CHEMISTRY

Structure-Activity Studies on Alpha-Conotoxins

(2012) Markus Muttenthaler et al.   CURRENT PHARMACEUTICAL DESIGN

γ-Aminobutyric Acid Type B (GABAB) Receptor Expression Is Needed for Inhibition of N-type (Cav2.2) Calcium Channels by Analgesic α-Conotoxins

(2012) Hartmut Cuny et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Intrathecal α-conotoxins Vc1.1, AuIB and MII acting on distinct nicotinic receptor subtypes reverse signs of neuropathic pain

(2012) I.A. Napier et al.   NEUROPHARMACOLOGY

GABA and central neuropathic pain following spinal cord injury

(2011) Young S. Gwak et al.   NEUROPHARMACOLOGY

The Engineering of an Orally Active Conotoxin for the Treatment of Neuropathic Pain

(2010) Richard J. Clark et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Analgesic α-conotoxins Vc1.1 and Rg1A inhibit N-type calcium channels in sensory neurons of α9 nicotinic receptor knockout mice

(2010) Brid Callaghan et al.   Channels

The evidence for pharmacological treatment of neuropathic pain

(2010) Nanna Brix Finnerup et al.   PAIN

A novel mechanism of inhibition of high-voltage activated calcium channels by α-conotoxins contributes to relief of nerve injury-induced neuropathic pain

(2010) Harry Klimis et al.   PAIN

Conopeptide characterization and classifications: An analysis using ConoServer

(2010) Quentin Kaas et al.   TOXICON

Alpha9 nicotinic acetylcholine receptors and the treatment of pain

(2009) J. Michael McIntosh et al.   BIOCHEMICAL PHARMACOLOGY

Scanning Mutagenesis of α-Conotoxin Vc1.1 Reveals Residues Crucial for Activity at the α9α10 Nicotinic Acetylcholine Receptor

(2009) Reena Halai et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Conotoxins: natural product drug leads

(2009) Reena Halai et al.   NATURAL PRODUCT REPORTS

Analgesic  -Conotoxins Vc1.1 and Rg1A Inhibit N-Type Calcium Channels in Rat Sensory Neurons via GABAB Receptor Activation

(2008) B. Callaghan et al.   JOURNAL OF NEUROSCIENCE

Binding Mode of α-Conotoxins to an Acetylcholine Binding Protein Determined by Saturation Transfer Difference NMR

(2008) Jan-Christoph Westermann et al.   PROTEIN AND PEPTIDE LETTERS